Norifaz (Risedronate Sodium)

Risedronate Sodium, the active ingredient in Norifaz, is a bisphosphonate presented as a oral formulation for oral use. It treats osteoporosis, Paget's disease of bone, and glucocorticoid‑induced osteoporosis in adult patients. GNH USA supplies Norifaz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norifaz is a bisphosphonate indicated for conditions involving abnormal bone remodeling. - Osteoporosis: improves bone mineral density and reduces the risk of vertebral and non‑vertebral fractures. - Paget's disease of bone: normalizes bone turnover and alleviates associated pain. - Glucocorticoid‑induced osteoporosis: prevents bone loss caused by long‑term steroid therapy.

Common side effects are generally mild and related to gastrointestinal tolerance or musculoskeletal discomfort.

Common Side Effects: - Upper gastrointestinal discomfort: nausea, abdominal pain, dyspepsia. - Constipation: difficulty passing stools. - Diarrhea: loose stools. - Musculoskeletal pain: bone or joint aches.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: death of jaw bone tissue. - Atypical femur fracture: unusual break in the thigh bone. - Severe esophagitis: inflammation or ulceration of the esophagus.

Before prescribing Norifaz, clinicians should evaluate several safety factors. - Renal function: assess kidney status prior to initiation. - Calcium/Vitamin D status: ensure adequate supplementation to support bone health. - Concomitant NSAIDs: monitor for increased gastrointestinal irritation. - Esophageal disorders: avoid use in patients with active esophageal disease. - Pregnancy and lactation: prescribe only when benefits outweigh potential risks. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Norifaz can interact with several medicines, requiring attention to timing and monitoring.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: markedly reduce risedronate absorption if taken together. - Calcium supplements: interfere with oral uptake; separate dosing by at least 2 hours. - High‑dose vitamin D: may increase risk of hypercalcemia.

Moderate Interactions (Monitor Closely): - NSAIDs: additive risk of gastrointestinal irritation or ulceration. - Corticosteroids: combined effect on GI mucosa may heighten ulcer risk. - Warfarin: monitor INR as bisphosphonates can affect coagulation parameters.